AbCellera Biologics Inc. Total Contract Liability
AbCellera Biologics Inc. (ABCL) had Total Contract Liability of $61.16 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability $61.16M.
- 2026-03-31: Contract with Customer, Liability $8.99M.
- 2025-12-31: Contract with Customer, Liability $17.03M.
- 2025-09-30: Contract with Customer, Liability $21.54M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2026-06-30 | $61.16M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $8.99M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $17.03M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $21.54M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $28.58M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $32.53M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $19.22M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $13.68M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $14.37M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $19.14M 10-Q · filed 2025-05-08 | |
| 2023-12-31 | $27.15M 10-Q · filed 2025-11-06 | |
| 2023-09-30 | $33.89M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $36.26M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $37.22M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $41.13M 10-Q · filed 2024-11-04 | |
| 2022-09-30 | $30.92M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $32.00M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $35.86M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $34.95M 10-Q · filed 2023-11-02 | |
| 2021-09-30 | $35.35M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $31.23M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $32.38M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $26.32M 10-Q · filed 2022-11-08 | $26.23M 10-Q · filed 2021-05-14 |
| 2020-09-30 | $26.94M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $28.91M 10-Q · filed 2021-08-13 | |
| 2020-03-31 | $28.98M 10-Q · filed 2021-05-14 | |
| 2019-12-31 | $5.54M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |